titlesubmit dateissue date
Now showing items 1-20 of 37
A network analysis to identify mediators of germline-driven differences in breast cancer prognosis.
A robust blood gene expression-based prognostic model for castration-resistant prostate cancer.
BMPs as therapeutic targets and biomarkers in astrocytic glioma
Cancer stem cells from human glioblastoma resemble but do not mimic original tumors after <i>in vitro</i> passaging in serum-free media
Cause-specific mortality after diagnosis of cancer among HIV-positive patients: A collaborative analysis of cohort studies.
Characterization of LEDGF/p75 genetic variants and association with HIV-1 disease progression
CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer
Chronic fatigue syndrome: aetiology, diagnosis and treatment
Chronic lymphocytic leukemia cells in lymph nodes show frequent NOTCH1 activation
Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk
Effect of vaccination, comorbidities and age on mortality and severe disease associated with influenza during the season 2016-2017 in a Spanish tertiary hospital.
Evaluation of mammographic density patterns: reproducibility and concordance among scales
Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "El Álamo III" retrospective study
Gene expression and immunohistochemical analyses identify SOX2 as major risk factor for overall survival and relapse in Ewing sarcoma patients
Genetic alterations of IDH1 and Vegf in brain tumors
Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy
Genetically Confirmed Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome
Impact of Frailty and Disability on 30-Day Mortality in Older Patients With Acute Heart Failure.
Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR Registry.
MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma